Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions. They found people taking the jabs were less likely to develop health problems like psychotic disorders, heart disease and dementia.